SI21079B - Formulacija, ki povecuje mobilizacijo - Google Patents

Formulacija, ki povecuje mobilizacijo Download PDF

Info

Publication number
SI21079B
SI21079B SI200120022A SI200120022A SI21079B SI 21079 B SI21079 B SI 21079B SI 200120022 A SI200120022 A SI 200120022A SI 200120022 A SI200120022 A SI 200120022A SI 21079 B SI21079 B SI 21079B
Authority
SI
Slovenia
Prior art keywords
stem cells
formulation
hematopoietic
hematopoietic stem
defibrotide
Prior art date
Application number
SI200120022A
Other languages
English (en)
Other versions
SI21079A (sl
Inventor
Laura Ferro
Roberto Porta
Massimo Iacobelli
Alessandro Massimo Gianni
Original Assignee
Gentium Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gentium Spa filed Critical Gentium Spa
Publication of SI21079A publication Critical patent/SI21079A/sl
Publication of SI21079B publication Critical patent/SI21079B/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Podan je opis metode za povecanje kolicine izvornih celic in zarodnih celic v perifernem krvnem obtoku pri sesalcih. Metoda je oznacena z administracijo defibrotid-a v kombinaciji ali v zaporedju z vsaj enim hematopoetskim faktorjem, prednostno G-CSF, ki ima sposobnost mobilizacije hematopoetskih zarodnih celic.

Claims (8)

  1. -1/1- SI21079 PATENTNI ZAHTEVKI 1. Formulacija označena s tem, da vsebuje aktivne komponente defibrotid in vsaj enega od hematopoetskih faktorjev s sposobnostjo mobilizacije hematopoetskih izvornih celic.
  2. 2. Formulacija po zahtevku 1, označena s tem, da je G-CSF hematopoetski faktor s sposobnostjo mobilizacije hematopoetskih izvornih celic.
  3. 3. Formulacija po zahtevku 1, označena s tem, daje vodna raztopina.
  4. 4. Formulacija po zahtevku 1, označena s tem, dajo predstavljajo dve ločeni komponenti za administracijo, ena, ki vsebuje hematopoetski faktor s sposobnostjo mobilizacije hematopoetskih izvornih celic, in druga, ki vsebuje defibrotid.
  5. 5. Formulacija označena s tem, da vsebuje defibrotid in vsaj enega od hematopoetskih faktorjev s sposobnostjo mobilizacije hematopoetskih izvornih celic, prednostno G-CSF, kot kombiniran pripravek za sočasno, ločeno ali zaporedno uporabo za povečanje zarodnih in/ali izvornih celic v periferni krvi sesalcev.
  6. 6. Formulacija po zahtevkih od 1 do 5, označena s tem, da vsebuje običajne dodatke polnila in/ali koadjuvanse.
  7. 7. Uporaba defibrotid-a v kombinaciji z vsaj enim od hematopoetskih faktoijev, ki imajo sposobnost mobilizacije hematopoetskih zarodnih celicah za pripravo formulacije sposobne povečati količino izvornih celic in/ali hematopoetskih zarodnih celic v perifernem krvnem obtoku sesalcev.
  8. 8. Uporaba po zahtevku 7, označena s tem, da je G-CSF hematopoetski faktor s sposobnostjo mobilizacije hematopoetskih izvornih celic.
SI200120022A 2000-04-18 2001-04-10 Formulacija, ki povecuje mobilizacijo SI21079B (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00830293A EP1147777A1 (en) 2000-04-18 2000-04-18 Combination of defibrotide and G-CSF and its use to activate haematopoietic progenitors
PCT/EP2001/004105 WO2001078761A2 (en) 2000-04-18 2001-04-10 Mixture of defibrotide and g-csf ant its use for activating haematopoietic progenitors

Publications (2)

Publication Number Publication Date
SI21079A SI21079A (sl) 2003-06-30
SI21079B true SI21079B (sl) 2006-08-31

Family

ID=8175292

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200120022A SI21079B (sl) 2000-04-18 2001-04-10 Formulacija, ki povecuje mobilizacijo

Country Status (31)

Country Link
US (1) US20040131588A1 (sl)
EP (3) EP1147777A1 (sl)
JP (1) JP5205668B2 (sl)
KR (1) KR100849491B1 (sl)
CN (1) CN1183962C (sl)
AT (2) ATE310532T1 (sl)
AU (2) AU5832201A (sl)
BG (1) BG107203A (sl)
CA (1) CA2406179C (sl)
CY (1) CY1104971T1 (sl)
CZ (1) CZ20023426A3 (sl)
DE (2) DE60140015D1 (sl)
DK (2) DK1276497T3 (sl)
EE (1) EE200200596A (sl)
ES (2) ES2252227T3 (sl)
HR (1) HRP20020835A2 (sl)
HU (1) HUP0300560A3 (sl)
IL (1) IL152328A (sl)
IS (1) IS2171B (sl)
MX (1) MXPA02010346A (sl)
NO (1) NO20024988L (sl)
NZ (1) NZ522016A (sl)
PL (1) PL358100A1 (sl)
PT (1) PT1621207E (sl)
RO (1) RO121006B1 (sl)
RU (1) RU2248216C2 (sl)
SI (1) SI21079B (sl)
SK (1) SK14892002A3 (sl)
UA (1) UA73566C2 (sl)
WO (1) WO2001078761A2 (sl)
ZA (1) ZA200208413B (sl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8771663B2 (en) 2000-04-18 2014-07-08 Gentium Spa Formulation having mobilising activity
EP1656156A2 (en) * 2003-08-13 2006-05-17 Children's Hospital Medical Center Mobilization of hematopoietic cells
EP1656451A2 (en) 2003-08-13 2006-05-17 Children's Hospital Medical Center Chimeric peptides for the regulation of gtpases
EP2103689A1 (en) * 2008-03-19 2009-09-23 Gentium S.p.A. Synthetic phosphodiester oligonucleotides and therapeutical uses thereof
RU2376985C1 (ru) * 2008-07-17 2009-12-27 Владислав Николаевич Ласкавый Средство для активации стволовых клеток
AU2010363814B2 (en) 2010-11-12 2016-05-19 Gentium S.R.L. Defibrotide for use in prophylaxis and/or treatment of Graft versus Host Disease (GVHD).
AU2012383169B2 (en) 2012-06-22 2017-12-21 Gentium S.R.L. Euglobulin-based method for determining the biological activity of defibrotide
EP3026122A1 (en) 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide
CN106567694A (zh) * 2016-11-14 2017-04-19 北京国泰通源技术有限公司 智能控水短节
CN110352246A (zh) * 2018-01-12 2019-10-18 赛尔美格公司 产生细胞囊和细胞囊管的方法
KR20220071274A (ko) 2019-11-13 2022-05-31 후지필름 가부시키가이샤 가식 필름, 성형물, 및 전자 디바이스

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2154279A1 (de) * 1970-11-03 1972-05-25 Crinos Industria Farmaco Medikamente für das fibrinolytische System
US3899481A (en) 1970-11-03 1975-08-12 Crinos Industria Farmaco Process for the controlled partial degradation of deoxyribonucleic acid extracted from animal organs
IT1043823B (it) * 1970-11-03 1980-02-29 Prephar Procedimento per l estrazione di acidi nucleici da organi animali
IT1206341B (it) 1984-02-16 1989-04-14 Crinos Industria Farmaco Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio.
US4694134A (en) 1985-05-28 1987-09-15 Ajax Magnethermic Corporation Apparatus for overheating edges of skelp for the production of compression welded pipe
US5223609A (en) 1986-04-17 1993-06-29 Crinos Industria Farmacobiologica S.P.A. Process for obtaining chemically defined and reproducible polydeoxyribonucleotides
IT1190313B (it) 1986-04-17 1988-02-16 Crinos Industria Farmaco Procedimento per l'ottenimento di polidesossiribonucleotidi chimicamente definiti e riproducibili e prodotto farmacologicamente attivo risultante
IT1223322B (it) * 1987-10-23 1990-09-19 Crinos Industria Farmaco Metodo per prevenire la formazione di coaguli sanguigni nel circuito extracorporeo di apparecchi di dialisi a composizione utile per esso
JP2907447B2 (ja) * 1988-08-24 1999-06-21 中外製薬株式会社 抗血栓剤
IT1231509B (it) * 1989-09-07 1991-12-07 Crinos Industria Farmaco Composizione farmceutica ad uso topico per la terapia della fragilita' capillare.
US5199942A (en) * 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
US5977083A (en) * 1991-08-21 1999-11-02 Burcoglu; Arsinur Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states
JP3021906B2 (ja) * 1992-01-28 2000-03-15 松下電器産業株式会社 電動調理機
JPH08127539A (ja) * 1994-10-31 1996-05-21 Ajinomoto Co Inc ヒトｉｌ−１１を含有する末梢血幹細胞増加剤
US5856444A (en) * 1994-11-30 1999-01-05 Chugai Seiyaku Kabushiki Kaisha Thrombocytopoiesis stimulating factor
CA2260014A1 (en) * 1996-07-10 1998-01-15 Meiji Milk Products Co., Ltd. Novel use of mk family as hematopoietic factor
AU1705599A (en) * 1997-11-26 1999-06-15 Allegheny University Of The Health Sciences Methods for mobilizing hematopoietic facilitating cells and hematopoietic stem cells into the peripheral blood
US6573372B2 (en) * 1999-01-07 2003-06-03 Heska Corporation Feline immunoglobulin E molecules and compositions there of

Also Published As

Publication number Publication date
IS6581A (is) 2002-10-14
CA2406179A1 (en) 2001-10-25
PL358100A1 (en) 2004-08-09
CN1434719A (zh) 2003-08-06
CA2406179C (en) 2012-03-27
JP2004500437A (ja) 2004-01-08
NO20024988D0 (no) 2002-10-16
JP5205668B2 (ja) 2013-06-05
ES2335776T3 (es) 2010-04-05
DE60115222T2 (de) 2006-08-10
EP1621207A2 (en) 2006-02-01
HUP0300560A2 (hu) 2003-06-28
RU2248216C2 (ru) 2005-03-20
IL152328A0 (en) 2003-05-29
ES2252227T3 (es) 2006-05-16
EP1276497A2 (en) 2003-01-22
CZ20023426A3 (cs) 2003-05-14
CY1104971T1 (el) 2010-03-03
RO121006B1 (ro) 2006-11-30
EP1621207B1 (en) 2009-09-23
WO2001078761A3 (en) 2002-01-24
CN1183962C (zh) 2005-01-12
SI21079A (sl) 2003-06-30
SK14892002A3 (sk) 2003-06-03
EP1147777A1 (en) 2001-10-24
DK1276497T3 (da) 2006-03-27
HUP0300560A3 (en) 2005-07-28
PT1621207E (pt) 2009-12-28
AU5832201A (en) 2001-10-30
WO2001078761A2 (en) 2001-10-25
DE60115222D1 (de) 2005-12-29
EP1621207A3 (en) 2006-11-22
UA73566C2 (en) 2005-08-15
AU2001258322B2 (en) 2006-03-16
EP1276497B1 (en) 2005-11-23
RU2002130719A (ru) 2004-03-27
ATE310532T1 (de) 2005-12-15
BG107203A (bg) 2003-05-30
DE60140015D1 (de) 2009-11-05
NZ522016A (en) 2004-10-29
EE200200596A (et) 2004-04-15
ZA200208413B (en) 2003-10-17
IL152328A (en) 2009-12-24
ATE443524T1 (de) 2009-10-15
MXPA02010346A (es) 2004-09-06
HRP20020835A2 (en) 2005-10-31
IS2171B (is) 2006-11-15
KR100849491B1 (ko) 2008-07-31
DK1621207T3 (da) 2010-02-01
KR20030010603A (ko) 2003-02-05
NO20024988L (no) 2002-12-02
US20040131588A1 (en) 2004-07-08

Similar Documents

Publication Publication Date Title
SI21079B (sl) Formulacija, ki povecuje mobilizacijo
HK1024865A1 (en) Pharmaceutical compositions comprising a mixture of autocross-linked hyaluronic acid and nonautocross-linked hyaluronic acid and their use for the treatment of arthropathies
UA29406C2 (uk) Складні ефіри трициклічних аміноспиртів
PT1377164E (pt) A eritropoietina melhora a toxicidade induzida pela quimioterapia in vivo
EA200200151A1 (ru) Сухая порошкообразная композиция
NZ237513A (en) Retinoic acid esters, preparation and pharmaceutical/cosmetic compositions thereof
FI962056A0 (fi) Uusi farmaseuttinen koostumus stabiilin jauheen valmistamiseksi, joka sisältää asetyylisalisyylihapon ja metoklopramidin yhdistelmän käsittävän aktiivisen aineosan
ZA973705B (en) Biologically active composition.
AU3548901A (en) Veterinary compositions for the treatment of parasitic diseases
ES296805A1 (es) Procedimiento para la preparaciën de una composiciën para la higiene de la piel
ES421570A1 (es) Un procedimiento para la preparacion de nuevos derivados de cianopregnenona.
YU79802A (sh) Formulacija sa aktivnošću mobilizacije
GB891554A (en) Galenic suppository containing salts of heparin
朱兆明 et al. CLINICAL USE OF HOMOGRAFT STORED BY VITRIFICATION
GB1014233A (en) Urea-containing diuretic compositions
GB821500A (en) Pharmaceutical compositions comprising benactyzine and meprobamate
HUT34871A (en) Fungicid preparations of synergetic effect containing several agents
GB1485383A (en) Injectable non-aqueous therapeutic compositions
JPS53144573A (en) Industrial preparation of 2-mercaptothiazoles

Legal Events

Date Code Title Description
IF Valid on the event date
OU02 Decision according to article 73(2) ipa 1992, publication of decision on partial fulfilment of the invention and change of patent claims

Effective date: 20060530

KO00 Lapse of patent

Effective date: 20091230